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REVIEW
Precision-cut intestinal slices: alternative model for drug transport, metabolism,
and toxicology research
Ming Li, Inge A. M. de Graaf and Geny M. M. Groothuis
Pharmacokinetics, Toxicology & Targeting, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
ABSTRACT
Introduction: The absorption, distribution, metabolism, excretion and toxicity (ADME-tox) pro-
cesses of drugs are of importance and require preclinical investigation intestine in addition to the
liver. Various models have been developed for prediction of ADME-tox in the intestine. In this
review, precision-cut intestinal slices (PCIS) are discussed and highlighted as model for ADME-tox
studies.
Areas covered: This review provides an overview of the applications and an update of the most
recent research on PCIS as an ex vivo model to study the transport, metabolism and toxicology of
drugs and other xenobiotics. The unique features of PCIS and the differences with other models
as well as the translational aspects are also discussed.
Expert opinion: PCIS are a simple, fast, and reliable ex vivo model for drug ADME-tox research.
Therefore, PCIS are expected to become an indispensable link in the in vitro–ex vivo–in vivo
extrapolation, and a bridge in translation of animal data to the human situation. In the future, this
model may be helpful to study the effects of interorgan interactions, intestinal bacteria, excipi-
ents and drug formulations on the ADME-tox properties of drugs. The optimization of culture
medium and the development of a (cryo)preservation technique require more research.
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The intestine is extensively involved in the transport,
metabolism, and toxicity of drugs after oral administra-
tion, which requires preclinical investigation. Various in
vivo and in vitro models (shown in Figure 1) have been
developed in the past, but each of these applications
has several limitations (as discussed in Section 2). In this
review, the application of the more recently developed
model of precision-cut intestinal slices (PCIS) for drug
transport, metabolism, and toxicology research for
drugs and other xenobiotics will be discussed.
The model of tissue slices was first invented in 1923
by Otto Warburg to measure cell metabolism and oxy-
gen consumption in tumor tissue [1] and further
explored by Hans Krebs to study amino acid metabo-
lism in various organs and species including human.[2]
However, the tissue slices at that time had severe lim-
itations, for example, rapid loss of viability and irrepro-
ducible thickness, due to the nonoptimized incubation
conditions and the fact that they were hand-cut using a
razor blade, respectively.
In 1980, Carlos Krumdieck developed a new semiau-
tomatic instrument, the Krumdieck tissue slicer, to
reproducibly prepare thin and precision-cut liver slices,
[3] and thereby initiated the revival of tissue slices in
collaboration with Klaus Brendel and various other
members of his laboratory.[4–8] This collaboration
resulted in optimization of the tissue viability (e.g. sub-
mersion in cold oxygenated buffer during slicing) and
increased reproducibility by enabling a well-defined
size by the semiautomatic slicing (e.g. 4–15 mm dia-
meter and 100–400 µm thickness). Thereafter, the appli-
cations of the precision-cut tissue slices (PCTS) were
widely explored not only in the area of cell metabolism
in healthy and cancer cells, but also in transport, meta-
bolism, and toxicity of drugs,[9–11] fibrosis,[12–14]
obstructive lung diseases,[15–17] and viral infec-
tions.[18]
Initially, the precision-cut technique was applied to
solid organs such as the liver and the kidney but not
applied to the intestine. Due to its structure as a hollow,
tender, long, highly differentiated, and delicate organ, it
appeared more difficult to slice and incubate. As a
result, intestinal slices were initially not produced with
a semiautomatic slicing instrument, but with a coring
tool and punched directly out of the intestinal wall and
thus had the full thickness of the intestinal wall.[5,19]
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However, they appeared to lose their viability rather
rapidly.[20] Up to now, applications of intestinal
punches are limited to studies on the metabolism of
cyclosporine A and tegaserod in human intestinal slices
[5,6,21] and the metabolic activation of carcinogens in
rat colon slices.[22]
The preparation of PCIS was introduced later by de
Kanter et al., who used low-gelling agarose to fill the rat
intestinal lumen and sliced the intestinal segments per-
pendicularly to the length of the intestine, resulting in
rings of tissue for rat PCIS.[20] This improvement proved
to be very valuable as it resulted in a better
reproducibility and tissue viability,[23] while at the
same time it was relatively simple and convenient to
prepare and use.[24] This improved preparation techni-
que for PCIS has been successfully applied to studies on
drug metabolism, induction, and inhibition, as reviewed.
[25] Later, this technique was applied to the intestine of
mouse,[10] human,[26,27] and, most recently, chicken.
[28] It should be noted that the preparation is slightly
different for human PCIS. Since the muscle layer is too
thick and the circumference of the lumen is too big to
slice a whole ring of the intestine, slices are produced
from sheets of intestinal tissue after the removal of the
muscle layer. The detailed procedures of preparation and
incubation of PCIS were extensively described by de
Graaf et al. [29] and are shown in Figure 2.
2. PCIS as alternative model to the
conventional methods
Many methods have been developed and successfully
applied to characterize and predict the absorption, dis-
tribution, metabolism, excretion, and toxicity (ADME-tox)
properties of new chemical entities (NCEs) and xenobio-
tics (Figure 1).[30–35] In vitro cell cultures and in vivo
animal models are the conventional methods that are
widely used in both academia and industry, and they are
well characterized. Among the various cell culture mod-
els, Caco-2 monolayer culture has been considered as
the ‘gold standard’ in studying intestinal disposition of
drugs in vitro.[36] However, these cell cultures have
some limitations that limit the accuracy of the prediction
for in vivo. In general, in vitro cell cultures do not reflect
the tissue multicellularity and three-dimensional (3D)
structure and some cell types lose their polarization.
Moreover, the expression levels of drug transporters
(DTs) and metabolizing enzymes (DMEs) deviate from
the natural expression.[37,38] On the other side of the
spectrum, the in vivo models retain the proper physiolo-
gical conditions, but the screening capacity is too low
Article highlights
● After the introduction of tissue slicer and agarose filling and
embedding, precision-cut intestinal slices (PCIS) has been estab-
lished as ex vivo model for the intestine, which can be easily
applied to the human intestine and that of various animals.
● As an alternative model, PCIS have an important potential for
absorption, distribution, metabolism, excretion, and toxicity
studies due to sufficient maintenance of tissue viability, activity
and functionality to perform toxicity and induction studies,
maintenance of cell polarity and cell–cell and cell–matrix con-
tacts, relatively easy and fast preparation, efficient use of the
scarce tissue resulting in 100–200 slices per experiment, applic-
ability to the human situation, and convenience in studying
regional and species differences, in compliance with replace-
ment, reduction, and refinement. However, its limitations
should also be taken into account.
● PCIS were applied to study drug transport related to efflux
transporters (P-glycoprotein (P-gp), multidrug resistance-asso-
ciated proteins) and influx transporters (apical sodium-depen-
dent bile acid transporter). The ex vivo assessment of the
transporters involved and the evaluation of the inhibitory
potencies of their inhibitors are expected to make more accu-
rate predictions for potential drug–drug interactions (DDIs) in
vivo.
● Applications of PCIS on drug toxicity were focused on drug-
induced gut injury by nonsteroidal anti-inflammatory drugs and
toxic bile acids. PCIS are also promising in evaluating the
toxicity of anticancer compounds.
● PCIS can be applied to predict DDIs by studying the induction
and inhibition of drugs on the activity of drug transporters and
drug metabolizing enzymes. Furthermore, the transport–meta-
bolism interplay, for example, P-gp/CYP3A interplay, and inter-
organ interactions can be studied in PCIS.
This box summarizes key points in the article.
Figure 1. Schematic classification of the current models to study the absorption, distribution, metabolism, excretion, and toxicity
properties drugs and xenobiotics in the intestine.
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and the cost, both in animal lives and in money, is much
higher. Moreover, applications of these in vivo models in
human are extremely difficult due to ethical constraints
and exceptionally high costs. To fill this gap, alternative
methods using intact tissue, such as everted sac, per-
fused intestinal loops, Ussing chamber, intestinal
punches, and, more recently, PCIS, have been developed
and are increasingly used to provide additional
Figure 2. Preparation and incubation of rat and human intestinal slices. Upper panel (a–h): preparation of rat intestinal cores. After
the fecal contents are removed from the intestinal segment (a), one side is tied (b). The segment is filled with liquid agarose
solution at 37°C (c) and cooled (d) to form a filled cylinder about 5 mm thick (e). After cutting the segments into two halves (f), a
pin is placed in the filled lumen (g) to fix the segment in the precooled cylindrical mold plunger (h). The mold is then filled with
agarose solution at 37°C. Middle panel (a–h): preparation of human intestinal cores. (a) Piece of human jejunum. Fat tissue is
removed and the intestine is opened (here the mucosal side is facing upward) (b). The segment is then fixed on a silicone mattress
on the precooled tissue-embedding unit with pins (c) and the muscular is gently cut (stripped) away (d, e). Thereafter, the stripped
intestine is cut into pieces of approximately 10 × 20 mm (f) and embedded with low-gelling agarose (g, h). Lower panel (i–l): slicing
and incubation of rat precision-cut intestinal slices. Agarose cooled in the mold (i). The plunger is removed from the mold and
transferred to the Krumdieck tissue slicer (j). Slices of 2–4 mg in wet weight are cut (k) and incubated in 12-well plates (l).
Reproduced with permission from [29].
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information on the intestinal handling of NCEs during
preclinical investigation. Recently, the use of stem cells
differentiated during culture to organoids has been
added to this spectrum of techniques.[39] However, up
to now these stem-cell-derived intestinal organoid have
not been fully characterized for drug metabolism and
transport function, and, moreover, similar to the Caco-2
model, they can at best represent only one specific
location in the intestine. Of these models, the PCIS
model combines the maintenance of tissue 3D structure
and multicellularity and physiological polarized expres-
sion of DTs and DMEs with a good level of reproduci-
bility and viability and highly efficient use of scarce tissue
and can represent all regions of the intestine. Analogous
to the model of precision-cut liver, lung, and kidney
slices, PCIS are believed to be a physiologically relevant
ex vivo model for the intestine, providing valuable infor-
mation on the ADME-tox functions of the intestine and
have recently also been presented as a disease model in
fibrosis research.[40]
2.1. Compliance with 3Rs
The principle of 3Rs (replacement, reduction, and
refinement) initiated by William Russell and Rex Burch
in 1959 [41] encourages the use of alternatives to ani-
mal testing in order to reduce the use of experimental
animals and also to improve their welfare and the
scientific quality of the experiments when the use of
animals cannot be avoided. Nowadays, the 3Rs are
respected more and more by research scientists and
in many countries they are explicitly taken up in the
legislation concerning animal use. PCIS seem to be in
good compliance with the 3Rs, most notably with the
reduction. The number of animals needed can be con-
siderably reduced when using PCIS, as from each region
of the intestine within one experiment one can easily
make >100 slices, that is, perform >100 tests. In addi-
tion, the other organs from the same animal, for exam-
ple, liver and kidney, can be simultaneously sliced for
studies on these organs. Replacement can be achieved
by the application of human PCIS, prepared from med-
ical waste tissue derived from surgical resections of
patients’ intestine. In addition, the use of human PCIS
provides direct human data overcoming problematic
translation due to species differences. Refinement can
be achieved in toxicity studies as the animals do not
have to be exposed in vivo to the test chemical, but the
PCIS are exposed ex vivo. The discomfort of the animals
is reduced to a minimum as there is only stress due to
handing and induction of anesthesia. PCIS can also be
made from diseased tissue to study disease mechan-
isms or potential drugs. It should be noted that in these
cases suffering of the animals cannot be avoided
completely because it requires animals with induced
intestinal disease, for example, dextran sulfate sodium-
induced colitis in mice [42] and trinitrobenzene sulfonic
acid-induced colitis in rats.[43] However, due to the
possibility to perform many studies in one animal, also
in these cases the total number of animals with dis-
comfort is reduced.
2.2. Technical considerations
One important feature for a good model is its robust-
ness and reproducibility. As mentioned above, >100
slices can be produced from each region of the rat
intestine. Thus, it is possible to perform many series of
tests with the slices from all intestinal regions of the
same rat and in triplicate, which improves the quality of
the results. In addition, the procedures of preparation
and incubation of PCIS are relatively simple and do not
require very expensive instruments. Based on our own
experience, after a short period of training, one
researcher can handle a middle-sized experiment (ca.
100 slices) in a few hours, while two researchers are
needed for a large experiment (up to 400 slices).
Compared to other tissue preparations and in vivo ani-
mal studies that consume a considerable amount of
time, technical and animal handing competences and
efforts, PCIS are relatively easy to handle. Moreover, the
procedures and protocols for PCIS are standardized and
published in Nature protocols.[29] For small animals, the
procedures are similar to those for rat PCIS, where
pieces of intestine are filled with and embedded in
agarose before slicing. For larger animals, for example,
pig, dog, and monkey, the procedure as described for
human PCIS, removing of the muscle layer and embed-
ding sheets of tissue in agarose, should be followed.
Slices should have a thickness of maximally 400 μm to
enable sufficient substrate and oxygen supply. As a
result, it is possible to compare the results from differ-
ent species and organs,[10,23,25,44–46] both qualita-
tively and, when the correct scaling factors are
applied, also quantitatively.[10,47]
Two incubation systems, the shaken multiwell-plate
and the perfused biochip,[48] currently coexist, but no
significant differences in ATP levels and metabolic rates
were found between the biochip and well plates up to
24 h (unpublished observation).
2.3. Viability of PCIS during culture
For models using tissue preparations, the viability dur-
ing culture is a crucial issue, which is less of an issue in
experiments with cell lines. Tissue viability in the
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Ussing chamber is generally limited to 2–4 h [47] and
in the gut sac model is <3 h,[49,50] possibly due to a
lack of oxygen supply and nutrient penetration into
the center of the relatively thick intestinal wall. In
contrast, in PCIS from rat small intestine and colon
the intracellular ATP content, a general viability mar-
ker, is retained until 8 and 24 h of incubation, respec-
tively.[51] In addition, it was found that the slice
content of ATP in PCIS of human and mouse small
intestine remains at a higher level during 24 h of
incubation than in rat PCIS.[27] Consistent with the
ATP content, also the morphology of the enterocytes
and the epithelium lining remains intact and the
mucus production by the goblet cells is maintained,
[27,52] although flattening and loss of villi, as well as
swelling and edema in the stroma, was observed.
Furthermore, live/dead staining (calcein acetoxy-
methyl ester (calcein-AM)/ethidium bromide) showed
that chicken embryo PCIS can remain viable for up to 4
days.[28] Our own observations using fixable-dye via-
bility staining also showed that only a few dead cells
could be observed in rat PCIS after 5 h of incubation
(unpublished observation). However, although the
expression of the housekeeping gene GAPDH remains
constant for up to 24 h,[51] the villin expression, gen-
erally considered as a marker for enterocytes,
decreased during 8–24 h incubation in rat small intest-
inal slices, in line with the observation of loss of cells
and appearance of debris, but was constant in colon
slices up to 24 h.[51] Furthermore, data on lactate
dehydrogenase leakage and alkaline phosphatase
activity of the rat intestinal slices also supported that
viability can be retained in rat PCIS for at least 8 h.
[27,51,52] The viability of rat PCIS during incubation is
also dependent on the preservation method applied
between the removal from the body and the prepara-
tion of the cores. Both the method of preparation of
the tissue and the composition of the preservation
solution appeared to influence the viability of slices
after 6 h of preservation. Enriched culture medium
(William’s medium E supplemented with additional
buffering, colloids, and impermeants) appeared to pro-
tect the tissue better than the organ preservation
solution University of Wisconsin.[53]
In general, rat PCIS also maintain a better viability
than rat punched intestinal slices, based on ATP, RNA
quality and morphology, no matter if the muscle layer
in the intestinal punches was stripped off or not.[20] It
can be speculated that the thickness of the punches of
intestinal tissue was too large to allow efficient supply
of oxygen and substrates to all the cells. Nevertheless,
the biotransformation activities of both in phase I, for
example, 7-ethoxycoumarin (7-EC) metabolism by
cytochrome P450 (CYP)1A, and phase II, for example,
7-hydroxycoumarin (7-HC) by UDP glucuronosyltrans-
ferase (UGT) and sulfotransferase (SULT), were compar-
able in the first 3 h of incubation.[20]
2.4. Functionality of PCIS during incubation
In general, good activities of DMEs and recently also
DTs in human and rat PCIS have been found. As
mentioned above, the PCIS were shown to have simi-
lar phase I and II metabolic activities as fresh
punches,[20] but substantially higher (ranging from
3-to 30-fold) than microsomes or S9 fractions pre-
pared from the intestine, after scaling based on the
relative protein content.[10] Both phase I and II meta-
bolism of several substrates were shown to be linear
during 180 min of incubation,[52] whereas the meta-
bolic rates remained constant up to at least 8 h.[51]
The stability of metabolic activity up to 8 h was in
line with the reported well-preserved viability and
indicated the unchanged abundance of the proteins
involved in drug metabolism. After 24 h of incuba-
tion, most phase I and II reactions decreased signifi-
cantly in rat and human jejunum PCIS, while phase II
conjugation was well preserved in the PCIS from
colon.[27,51]
The first data on the activity of DTs in PCIS became
available in 2011,[54,55] but no study has been pub-
lished yet on the stability of transport activity during
culture. Isolation of RNA for RT-PCR after 48 h of incu-
bation results in highly intact RNA,[40] and the expres-
sion of several genes coding for DMEs and DTs after
24 h of incubation was shown to be regulated by well-
known ligands of transcription factors, indicating fully
active gene transcription.[27,56–58] The mRNA expres-
sion of some genes like multidrug resistance-associated
protein (MRP)2 [59] and apical sodium-dependent bile
acid transporter (ASBT) [56] decreases during 24 h of
incubation, whereas others like MRP3 [59] increase.
Probably, this is a result of lack of appropriate ligands
for transcription factors in the medium. On the other
hand, it was also noticed that in the slices, even after
short incubation periods, a pro-inflammatory process
was induced, indicated by increased expression of
genes such as TNFα and IL6.[60] Possibly, this was
caused by the cold ischemia of the slices during pre-
paration and subsequent reperfusion during culturing.
In addition, Pham et al. recently reported on the upre-
gulation of genes associated with the initiation of fibro-
sis after 24 h of culture.[40] This indicates that PCIS may
in the future be used as disease model to test efficacy
of antifibrotic drugs.
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2.5. Regional differences
The intestine is a heterogeneous organ in which the
regional differences in structure and function, including
the expression of DTs and DMEs, are prominent.[61,62]
Most of these differences have been found by analyzing
mRNA expression or protein abundance. However, it is
largely unknown to what extent the differences in
expression levels (mRNA and/or protein abundance) of
DTs and DMEs also represent their functional differ-
ences. A discrepancy between protein abundancy and
transport activity can be anticipated as it has been
demonstrated that the transporters are not solely loca-
lized at the plasma membrane but also intracellularly.
[63] PCIS offer an excellent opportunity to study these
regional differences at the level of activity of DTs and
DMEs and to predict the consequences of the hetero-
geneity of activity and local drug concentration in the
lumen on the intracellular and systemic exposure to
drugs and their metabolites. It is evident that neither
cell lines nor stem-cell-derived organoids can represent
these regional differences.
When using tissue of experimental animals, all
regions can be studied with tissue from one animal in
one experiment with PCIS. However, the likelihood of
obtaining tissue from several regions of the human
intestine is not high. Most tissue is obtained from
patients undergoing partial resections, and the tissue
remaining for research after sampling for the patholo-
gist is usually limited to one of the regions. Therefore,
due to the large interindividual differences in humans,
one needs at least tissue from five or more patients for
each region before a significant conclusion can be
drawn on regional differences in the human intestine.
2.6. Species differences
Isoforms, expression levels and activities of DTs and
DMEs, are considerably different between animals and
humans.[46] For this reason, unexpected issues related
to ADME-tox of new drugs form one of the major
hurdles during preclinical investigations. Methods
using human tissue could overcome extrapolation diffi-
culties between humans and animals, but many ex vivo/
in vivo models are impossible to perform with humans
for ethical reasons or are technically difficult and expen-
sive.[64] The PCIS method can be easily applied to
human tissue since practically the same technique is
used for all species (see Section 2.2). Data on transport,
metabolism, and toxicity in human PCIS are now slowly
appearing in the literature (see below), and more quan-
titative differences between animal and human data
will be identified in the near future. Furthermore, how
these results correlate with in vivo data and how they
can be applied in the drug development process should
be further explored.
3. Application of PCIS on drug transport,
metabolism, and toxicity
Although the awareness of the importance of the intes-
tine in drug ADME-tox has been rising in the last dec-
ade,[65–67] PCIS are still used less often than slices of
liver and kidney. In the past decade, PCIS were devel-
oped as ex vivo model to study drug metabolism and
toxicity [10,11,20,27,51,52,68] and, most recently, drug
transport.[54,55]
3.1. Application of PCIS for drug transport
Recently, studies were initiated to measure DT activity
in PCIS, but they are still very limited to date. Many
influx transporters are expressed on the apical mem-
brane of intestinal epithelial cell and have important
physiological functions. The activity of uptake transpor-
ters can be measured directly by analysis of the
increase in slice content after incubation with different
concentrations of the substrate and after different time
points. Active and passive uptake can be distinguished
by incubation at 4°C and 37°C and specific inhibitors
can be used to identify the transporter involved.
Recently, the uptake of bile acids in PCIS was studied
using cholic acid, deoxycholic acid (DCA), and tauro-
cholic acid.[69] In PCIS of rat and human ileum, the
active uptake mediated by ASBT could be clearly dis-
tinguished from passive uptake by parallel incubation
at 37°C and 4°C, and as expected, the involvement of
active uptake was larger for the hydrophilic taurocholic
acid than for the other two more hydrophobic bile
acids. The uptake in the PCIS of jejunum and colon
appeared mostly mediated by passive diffusion, which
is in line with the fact that ASBT is specifically expressed
in the ileum and virtually absent in the other intestinal
regions. These data indicate the applicability of PCIS for
the study of the activity of uptake transporters.
Direct measurement of excretion from slices into the
medium is hampered by the relatively large volume of
medium compared to the low amount of tissue and is
thus limited by the detection method for the substrate.
Therefore, up to now the involvement of efflux trans-
porters has only been studied indirectly by the accu-
mulation of the substrate in the PCIS and the influence
of inhibitors of the transporter on the accumulation.
Possidente et al. used this method to show the applic-
ability of rat jejunum PCIS for the interactions of xeno-
biotics with efflux transporters, using calcein-AM as
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probe, which is a substrate of P-glycoprotein (P-gp) and
is metabolized in the cells to calcein, which is a sub-
strate of MRPs.[55] Inhibitors of both P-gp and MRPs
exhibited their inhibitory effects by increasing the intra-
cellular retention of calcein. The enhanced accumula-
tion was concentration dependent and the potency of
inhibitors could be quantified as apparent half maximal
inhibitory concentration (IC50) values.
P-gp activity along the different regions of the intes-
tine and the inhibitory potencies of several drugs was
studied in rat [54] and human (manuscript in prepara-
tion) PCIS ex vivo using rhodamine 123 (R123), a specific
P-gp substrate. Using fluorescence microscopy, it could
be confirmed that the enterocytes in the PCIS are the
cells involved in the transport of the P-gp substrate.
Regional differences in P-gp activity were demonstrated
in rat and human PCIS by the increase in accumulation in
the tissue in the presence of an inhibitor. The P-gp
activity was found to be in ileum > jejunum > duode-
num ≥ colon. The increase in tissue accumulation corre-
lated with the level of P-gp expression shown in vivo.[70]
Interestingly, the regional differences of P-gp activity
were larger in the human intestine than in the rat tissue.
This shows the relevance of the use of human tissue for
more accurate predictions from in vitro to in vivo. The
rank order of the inhibitory potency of several well-
known Pgp inhibitors, reflected by the IC50, was consis-
tent with literature reports and comparable in rat and
human PCIS, suggesting relatively little differences in the
affinity of these inhibitors for human and rat P-gp. This is
in line with the findings of Sugimoto et al., who found
similar inhibition of rat and human P-gp by verapamil,
ketoconazole, and quinidine, but not for cyclosporine A.
[71] The IC50 obtained in PCIS studies is an apparent IC50
as it does not reflect the concentration at the active site
of the transporter, but takes into account the uptake,
metabolism, and excretion of the inhibitor. This makes
the IC50 obtained in PCIS a more physiologically relevant
parameter as these processes also play a role in vivo.
In a similar study, the P-gp-mediated excretion of qui-
nidine, a selective P-gp substrate as well as CYP3A4 sub-
strate, was studied in rat (manuscript in preparation) and
human [72] PCIS. Similar to R123, the quinidine accumula-
tion could be enhanced by specific and nonspecific P-gp
inhibitors. Although quinidine undergoes metabolism by
CYP3A4, the intracellular content of quinidine appeared
to bemainly determined by transport by passive diffusion
and active P-gp efflux. Interestingly, P-gp inhibition
resulted in a marked, more than expected based on the
increased quinidine concentration, increase of the intra-
cellular quinidine hydroxyl metabolite concentration,
indicating that this metabolite apparently is also a P-gp
substrate.
These results show that PCIS are a promising tool
for further studies to elucidate the involvement of
DTs for new drugs along the length of the intestine.
However, it should be noted that no distinction can
be made between transport by basolateral and apical
transporters for a compound that is a substrate of
both, unless specific inhibitors are used. As it was
evident from the studies with quinidine, the accumu-
lation of the probe in PCIS can be influenced by
other related process, like other DTs and DMEs.
Thus, the use of selective inhibitors is critical for
identification of the transporters involved. However,
this complexity of the physiological conditions also
indicates the limited relevance of Caco-2 and other
cell lines for the prediction of in vivo transport. To
date, no comparison between transporter activity ex
vivo and in vivo is available yet.
3.2. Application of PCIS for drug metabolism
Drug metabolism in the intestine has been known for
decades but was underestimated for a long period of
time. However, studies with human PCIS have shown
that the activity of CYP3A4 calculated per enterocyte of
the human small intestine may even be similar to or
higher than in the hepatocytes. In general, it became
evident that intestinal metabolism plays a more promi-
nent role relative to the liver in man than in the rat.[47]
Also, Martignoni et al. [10] reported in studies with rat
and mouse precision-cut liver and intestinal slices that
the metabolite formation rate (expressed per mg pro-
tein) of most CYP3A substrates was higher in liver slices
than in PCIS, but the formation of 3OH-quinidine was
threefold higher in rat intestinal than in rat liver slices,
while that of nor-verapamil was comparable. Taking
into account that the enterocytes are exposed to
much higher concentrations of drugs and xenobiotics
taken orally than hepatocytes, their contribution to
first-pass metabolism can be very high and is thus
relevant to study.
Van de Kerkhof et al. [52] were the first to investi-
gate gradients of drug metabolism along the intestinal
tract with PCIS using three model compounds, cover-
ing several phase I and II metabolic routes, that is, 7-EC
(substrate for CYP1A mainly), 7-HC (substrate of UGT
and SULF), and testosterone (substrate for several CYP-
isoforms and hydroxysteroid dehydrogenase). As
reviewed by van de Kerhof et al.,[47] gradients in
phase I and II metabolism from the duodenum toward
the colon were shown to be clearly different for the
different enzymes: CYP3A4, 2C8, 2C9, and CYP2D6 are
highest in the proximal regions of the small intestine
and decrease toward the colon, whereas CYP2S1 is
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equally expressed in all regions. In contrast, CYP2J2
and CYP3A5 as well as many (but not all) of the UGT
and SULT isoforms show an increasing gradient with
higher activity in the distal part.
The biotransformation of diclofenac into the 4ʹ-OH
and 5-OH metabolites and acyl glucuronide diclofenac
was investigated in rat [73,74] and human PCIS [75] and
also showed a higher rate of metabolism in human than
in rat tissue. Moreover, the different metabolic routes
could be specifically inhibited by specific inhibitors. In
contrast, the hydroxylation of a cannabinoid receptor 1
antagonist was higher in rat than human intestine.[76]
In the latter study, the effect of drug formulation on the
metabolite formation was evaluated as a surrogate end
point for absorption. The enhanced dissolution rate of
nanoparticles resulted in a higher uptake rate and,
consequently, in an increased metabolite formation,
which was in line with the results from Ussing chamber
using human tissue and rats in vivo, which indicates a
potential new application of the use of PCIS for absorp-
tion studies.
3.3. Application of PCIS for the study of drug–drug
interactions
Drug–drug interactions (DDIs), as a result of the induc-
tion or inhibition of DTs and DMEs as well as due to
transport–metabolism interplay, can considerably
influence the ADME process.[77] Thus, as the effect
of DDIs depends on both the relative affinity of the
different drugs and the abundance of the proteins
involved, the presence and physiological abundance
of all DTs and DMEs, and the required cofactors, is
critical for the accurate evaluation of the risk of poten-
tial DDIs. Many exogenous and endogenous com-
pounds, such as the ligands of nuclear receptors
(NRs), can regulate the expression of DTs and DMEs
in the intestine. Several studies have now shown that
DDIs based on induction can be successfully studied in
PCIS. Induction of expression and activity of DMEs by
β-naphthoflavone, dexamethasone, rifampicin, pheno-
barbital, indirubin, budesonide, pregnenolone-16a car-
bonitrile, and 1,25(OH)2D3 were shown in PCIS of rat
and human tissue.[27,51,57] These substrates are
ligands for the most relevant NRs such as the aryl
hydrocarbon receptor (AhR), the glucocorticoid recep-
tor (GR), the pregnane X receptor (PXR), the vitamin D
receptor (VDR), and the constitutive androstane recep-
tor (CAR). The regulation appeared different for the
different segments of rat and human intestine, and
the changes did not parallel the expression levels of
the NR.[57] The results of these studies showed that
PCIS can be used for predictions of DDIs that are
mediated by most of the relevant NRs such as AhR,
GR, PXR, VDR, and CAR.
Khan et al. studied the regulation of mRNA expres-
sion of bile acid transporters, for example, organic
solute transporter α/β (OSTα/β), MRP2, MRP3, and
ASBT in rat jejunum, ileum and colon and in human
ileum.[56] The results showed that the mRNA expres-
sion of OSTα/β was positively regulated by FXR and
GR ligands in rat and human tissue but negatively
regulated by 1,25(OH)2D3, a VDR ligand, in rat intes-
tine but not in human ileum.[56] The FXR/VDR ligand
lithocholic acid (LCA) was found not only to regulate
the expression of these bile acid-related transporters
in a species- and organ-dependent manner, but also
influence the expression of the enzymes related to
bile acid metabolism (CYP3A isoforms), synthesis
(CYP7A1), and related NRs,[59] showing profound
species differences and a complex network of induc-
tion.[57]
As discussed above, PCIS have greatly contributed to
extend the knowledge about the involvement of NRs in
the regulation of DTs and DMEs. The potential of rat
and human PCIS as a model to detect inhibition-based
DDIs has also become evident recently.[10,46,73,75] In
conclusion, PCIS have a great potential to serve as a
screening model for inducers and inhibitors of metabo-
lism and transport .
Recently, PCIS were used to study the transport–
metabolism interplay between DTs and DMEs. The
most well-known interplay, between intestinal P-gp
and CYP3A, has been studied in rat (manuscript in
preparation) and human PCIS.[72] Selective P-gp inhibi-
tors did not only enhance the tissue accumulation of
quinidine, a dual substrate of P-gp and CYP3A, but also
consequently increased the production of 3OH-quini-
dine. However, as many P-gp inhibitors are dual inhibi-
tors of P-gp and CYP3A, this increase of CYP3A
metabolism by P-gp inhibition is dependent on the
relative inhibitory potency of the inhibitor for P-gp
and CYP3A, Thus, ketoconazole inhibited CYP3A much
more than P-gp and resulted in a decreased metabo-
lism of quinidine despite increased quinidine accumula-
tion due to P-gp inhibition. It is evident that the result
of this interplay is strongly dependent on the relative
expression of P-gp and CYP3A, which is different in the
different intestinal regions. To fully predict and under-
stand the in vivo effects of this interplay, PCIS obtained
from all different regions should be applied. Studies
with Caco-2 cells or organoids may be less useful here
as they do not express these different ratios of P-gp and
CYP3A .
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3.4. Application of PCIS on drug toxicity
Drug-induced organ injury is a significant safety issue in
pharmaceutical development and clinical therapy.[78]
As a multifaceted process, it involves numerous cell
types and mediators, and is often mediated by forma-
tion of reactive metabolites, and thus cannot be well-
studied in in vitro cell cultures, but requires models that
represent the multicellular, structural, and functional
features of in vivo tissue. Moreover, such models should
be viable for at least 24 h to allow toxicity to develop.
Therefore, PCTS, which meet these requirements, are
increasingly investigated as an alternative and promis-
ing model for elucidating the mechanisms of drug-
induced organ injury.
Key target organs for drug-induced toxicity often are
those highly exposed to the toxin and include the liver,
kidney, and intestine. As drug-induced liver injury (DILI)
is one of the main reasons for failures in clinical trials
and the withdrawal of drugs from the market, toxicity
on liver/hepatocytes has been widely studied.
Meanwhile, drug-induced gut injury (DIGI) remains lar-
gely unstudied during preclinical investigations. This is
partly because the syndromes of DIGI, for example,
abdomen discomfort, ulcer, diarrhea, and bleeding, are
relatively mild compared to DILI. Another reason may
be that the intestinal epithelium is the most rapidly self-
renewing tissue in adult mammals due to the contin-
uous proliferation and differentiation of stem cells in
the crypts. As a result, the mild-to-medium-injured
intestine can be rapidly repaired by the regeneration
of enterocytes after several days of injury.
Although the syndromes of DIGI are mild, its preva-
lence is actually high and causes considerable discom-
fort to patients. For example, nonsteroidal anti-
inflammatory drugs (NSAIDs) can cause a high rate
(55–75%) of abnormalities on the lower GIT,[79,80]
whereas bleeding and ulceration occur in the upper
GIT.[81] However, it is surprising that the intestinal
toxicity of drugs is so little investigated preclinically,
which is at least partly due to the lack of suitable in
vitro models. Most of the existing models do not have a
sufficient viability and/or lack the appropriate DME and
DT expression. Therefore, PCIS were recently presented
as a model to study DIGI.[68,73,75] DIGI by NSAIDs
[73,75,82] and paracetamol [82] was evaluated with rat
and human PCIS using ATP depletion and morphologi-
cal evaluation of changes together with the biomarkers
of ER stress, mitochondrial injury, and oxidative stress as
indicators, and their relative toxic potential was shown
to be largely in line with the in vivo toxicity [73]
(Figure 3). The injury to the epithelial cells by diclofenac
was shown to occur at lower concentrations in rat than
in human PCIS. Interestingly, it could be shown that the
diclofenac metabolites did not contribute substantially
to the gut injury,[73,75] but that diclofenac is directly
toxic to the intestine.
Furthermore, DIGI by ketoconazole was observed in
rat and human PCIS (unpublished data) in line with the
clinical reports about the gut side effects of ketocona-
zole. In addition, PCTS from rat colon, liver, and kidney
were used to test the toxicity of new potent anticancer
gold(I) compounds on healthy organs. Monitored by
the depletion of intracellular ATP, the colon was
shown to be more resistant to the two metallocom-
pounds than the liver and kidney.[44]
Also, several bile acids are well known for their
intestinal cytotoxicity, such as LCA and DCA.[83] While
the nontoxic bile acids, taurocholic acid and cholic acid,
had no influence on the intracellular ATP and morphol-
ogy of rat PCIS after 1 h incubation with concentrations
up to 2 mM, rapid loss of ATP and morphological
change was induced by DCA within 10 min,[69] as
shown in Figure 4. Future research is needed to further
elucidate the potential of the PCIS to predict toxicity of
drugs and other xenobiotics in the human intestine and
to reveal the mechanisms of DIGI.
3.5. Other applications of PCIS
A promising new application of PCTS is in studying
interorgan interactions, such as intestinal induction
and/or toxicity of hepatic metabolites, or vice versa,
by co-incubation of PCTS from different organs. This
was investigated for the first time with a microfluidic
device, perfusing an intestinal slice and a liver slice
sequentially (Figure 5), showing that chenodeoxycholic
acid could upregulate the expression of fibroblast
Figure 3. Nonsteroidal anti-inflammatory drug (NSAID)-induced
toxicity in precision-cut intestinal slices (PCIS). NSAIDs (difluni-
sal, indomethacin, diclofenac, naproxen, and aspirin) induce
concentration-dependent decrease of ATP in rat PCIS after
5 h of incubation. Data are normalized to the vehicle controls
(5 h incubation without compounds). Data represent the aver-
age ± SEM (n ≥ 5). Reproduced with permission from [73].
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growth factor 15 by the intestinal slice, which resulted
in a downregulation of the bile acid synthesis enzyme,
CYP7A1, in the liver slices.[48]
New applications of PCIS as disease model have also
been explored. Intestinal diseases, such as Crohn’s dis-
ease, colitis, intestinal fibrosis, and inflammatory bowel
disease, are a major health burden. However, the
mechanisms of many diseases are still not fully under-
stood, partly due to the lack of relevant in vitro and in
vivo models. Recently, Pham et al. showed the applica-
tion of PCIS of rat, mouse, and human intestine as a
novel ex vivo model that can mimic the early onset of
the fibrosis process in the intestine [40] by monitoring
several fibrosis marker genes. TGF-β1 was found to
induce the gene expression of the fibrosis markers in
rat and mouse PCIS but not in human PCIS.
Furthermore, PCIS were recently prepared from the
fibrotic intestine of Crohn’s disease patients to study
late-stage human intestinal fibrosis and to test the
efficacy of antifibrotic drugs.[84]
PCIS from chicken embryo intestine were used to
study the infection by avian influenza virus.[28] The
intestinal epithelial cells in chicken embryo PCIS remain
viable for up to 4 days and are thus suitable for such
infection studies. The epithelial cells at the tips of the
villi were shown to be susceptible to infection by an
avian influenza virus of the H9N2 subtype.
Finally, it could be very interesting to investigate the
potential of PCIS to study the microbiome–tissue inter-
actions, but no such studies have been published to
date. But similar co-culture studies have been performed
in other models using cell lines from intestine.[85]
Figure 4. The toxicity of bile acids cholic acid (CA), taurocholic acid (TCA) for 1 h and deoxycholic acid (DCA) for 10 min in rat
precision-cut intestinal slices. Upper panel: a significant decrease of ATP was seen already after incubation for 10 min with 2.0 mM
DCA, whereas 2.0 mM CA and TCA were not toxic even after 1 h DCA. Lower panel: DCA, but not CA and TCA, caused flattening of
epithelial cells and discontinuous epithelial lining (haematoxylin and eosin staining).
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4. Limitations
Like all in vitro and ex vivo models, the PCIS model has
certain limitations.
Due to the perpendicular cutting of the PCIS, both
the mucosal and serosal side of the tissue are exposed
to the same medium. As a result, vectorial transport of
drugs across the gut wall cannot be studied with PCIS.
Likewise, the excretion of the parent drug and metabo-
lite(s) to either the mucosa or serosa compartment
cannot be discriminated. However, the Ussing chamber
and everted sac preparations still retain this possibility.
Vickers et al. recently reported the incubation of
punched intestinal tissue clamped between dual-rotat-
ing chambers, in which cyclosporine A was added to
the donor compartment and transported through the
tissue to the acceptor compartment.[86] This technique
is similar to the Ussing chamber; however, in the rotat-
ing chambers, the intestinal surface is not fully sub-
merged in medium while the two chambers are
rotating synchronously. No comparative study has
been reported yet between these two systems.
Another issue that one should bear in mind is the
change in expression of DTs, DMEs, and NRs during
culture. These changes may influence the activities of
the proteins involved in transport and metabolism in
the PCIS and ultimately may affect the generation of
toxic metabolites during culture. Further optimization
of the culture medium might be helpful to improve the
stability of the activity of the DTs and DMEs. For
instance, it is known that the addition of certain bile
acids (ligands of NRs) could help to maintain bile acid-
related transporters and synthesis enzymes.[59] Also,
the addition of indirubin, an endogenous ligand of
AhR, to the incubation medium retained CYP1A1
expression during incubation.[51]
Currently, the availability of human PCIS is limited
due to the scarcity of human intestinal tissue and the
lack of adequate (cryo)preservation methods. This
could be solved by the establishment of tissue banks
together with the development of good (cryo)preser-
vation protocols for PCIS. The latter will also be favor-
able for the application of PCIS from other species like
dog, monkey, or pig so that they could be optimally
used at any time and at any location. The relatively
short time that intestinal tissue can be preserved with-
out variable degrees of tissue injury is also a big
Figure 5. Schematic view of the biochip with three sets of two sequentially perfused chambers, with medium flowing (flow rate of 10
µL/min) first through the chamber with an intestinal slice and subsequently through the chamber with a liver slice. Modified from [48].
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challenge for small bowel transplantation, mainly due
to the sensitive nature of the intestine to the ischemia-
reperfusion injury.[87] The research with PCIS would
greatly benefit from both improved cold preservation
methods and a suitable cryopreservation protocol. Till
now, no cryopreservation technique has been
reported that can assure good viability and activity of
PCIS after storage.
The relative short maintenance of viability of PCIS
up to 24 h limits its application in chronic toxicity
testing. Better culture conditions should be developed
to improve the lifetime of the slices. New promising
models have recently been developed such as the
‘gut-on-a-chip’ and intestinal organoids with longer
survival time, but up to now they have not been fully
characterized with respect to ADME-tox properties.
Sato et al. developed an interesting in vitro intestinal
model in which stem cells can differentiate into enter-
ocytes, goblet cells, and enteroendocrine cells under
the proper conditions and furthermore self-organize
into organoids with a crypt-like domain and villus
structures with a long-term survival of several
months.[39] These intestinal organoids may serve as
a physiologically relevant alternative method for large-
and mid-scale in vitro testing of intestinal epithelium-
damaging drugs and toxins and for the investigation
of cell death pathways.[88] However, the feasibility of
its applications to ADME needs further exploration and
validation as the expression and activity of DMEs and
DTs in these intestinal organoids are unknown, but can
at best represent one of the regions of the intestine
only.
5. Translational importance
As described in the sections above, many differences
in drug transport, metabolism, and toxicity in the
intestine have been identified between experimental
animals and human, making predictions from animal
studies to the human situation hazardous. The data
collected so far from studies with human PCIS clearly
indicate that this ex vivo model has the potential to
predict these functions for the human intestine both
for drugs and for other xenobiotics such as food com-
pounds and environmental contaminants. Because the
PCIS can be made from each of the regions of the
human intestine, a better translation to the in vivo
situation can be made compared to the use of
human cell lines. In addition, mechanistic studies on
drug- and xenobiotic-induced intestinal toxicity can be
performed in human tissue, which provide useful data
for the interpretation of clinical findings and for the
risk/benefit assessment of new drugs and food
components and the risk assessment for environmen-
tal toxins.
6. Conclusions
PCIS are a simple, fast, and reliable ex vivo model to
study the transport, metabolism, and toxicity of drugs
taking advantage of the physiological expression of
intestinal transporters and metabolizing enzymes. This
model can also be used to predict transporter- and
enzyme-mediated DDIs. Moreover, it is notably valuable
to study the regional gradients of activity of intestinal
transporters and metabolizing enzymes from the duo-
denum to the colon. Furthermore, the same technique
can be applied to the intestine from human and experi-
mental animals. Therefore, it is also a very useful tool to
investigate species differences in ADME-tox profiles.
7. Expert opinion
PCIS are discussed and highlighted as a promising
method for drug ADME-tox studies in the intestine to
be used as alternative to the in vitro cell culturing and
in vivo animal modeling, which are conventionally used
in academia and industry. They show relatively good
viability and functionality up to 8–24 h of incubation.
Due to the physiological levels of DTs and DMEs in
PCIS, at least during the first hours of culturing, they
can provide physiologically relevant results, including
metabolic profiles, induction and inhibition potency,
and local drug/metabolite exposure, and can represent
the functional differences between duodenum, jeju-
num, ileum, and colon. Therefore, PCIS are expected
to serve as a translational model and a bridge between
animal and human. The development of substrates and
inhibitors with higher specificity for the enzymes and
transporters could be instrumental to identify the influ-
ence of the proteins involved in the disposition of a
certain substrate. In addition, PCIS made from the intes-
tine of genetic-deficient animals such as the Mrp2−/- rat
or genetically modified animals (i.e. Mdr1a knockout
mouse) can be helpful to identify transporters involved
in the transport of a drug under study.[74]
The sensitive nature of the intestine necessitates to
monitor the quality of the intestine and the viability of
PCIS using viability markers, for example, the intracel-
lular ATP and morphology, in each experiment and for
every compound of interest. Moreover, a further opti-
mization of culture medium would be very useful for
maintenance not only of viability but also of DME and
DT activity. Addition of supplementary compounds,
such as ligands for the nuclear factors involved in reg-
ulation of the DME and DT, into the medium to
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optimize the culture conditions of PCIS should be inves-
tigated for each species separately since rat PCIS seem
more vulnerable in the currently used medium
(William’s medium E) compared to mouse and human
PCIS.
Extension of the viability is also instrumental for
studies on DIGI, which were up to now limited to the
short-term effects of NSAIDs and bile acids. Future
applications may lead to the discovery of mechanisms
of damage using transcriptomics technologies and of
new protecting drugs for ischemia-reperfusion injury,
which would be useful also for transplantation pur-
poses.[53]
The very efficient use of human tissue makes the PCIS
the preferred model for translational studies. However, as
human intestinal tissue is scarce and not widely available,
PCIS may be also applied to identify other animal species
that in some aspects may be more similar to human than
rat or mouse, for instance, monkey or (mini)pig.
The wider application of PCIS would certainly ben-
efit from the development of better cold- and cryo-
preservation techniques. Development of long-term
preservation technologies for PCIS hopefully will ben-
efit from the fast-growing knowledge of cryopreserva-
tion techniques. When cryopreserved viable PCIS,
especially human PCIS, become available at any time
and location, a larger application in academia and
industry for the ADME-tox tests during drug develop-
ment will emerge.
The co-culture of PCIS with intestinal bacteria will be
a promising new area since the microbiome plays an
important role in the intestinal metabolism and toxicity.
The gut flora can contribute to the generation of toxic
metabolites that may injure the intestine.[89] The gut
microenvironment was also incorporated in the ‘human
gut-on-a-chip’ microdevice [90,91] in which Caco-2 cells
formed four different types of differentiated epithelial
cells and recapitulated the structure of intestinal villi. In
this system, the gut microenvironment was recreated
with flow of fluid and peristaltic motions, together with
the co-culture of normal intestinal bacteria on the lumi-
nal surface.
Selection of slices with and without Peyer’s patches,
aggregations of lymphoid cells that are usually found in
the ileum, may allow us to investigate the influence of
the immunological function of the Peyer’s patches on
the intestinal metabolism and transport function and
on DIGI.
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